Treating primary bone cancer: The potential of listeria-based bioengineered bacterial immunotherapy

Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. It mostly affects children and young adults under 20 years of age. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Paul Romness, president and CEO of OS Therapies, a company focused on the identification, development, and commercialisation of treatments for osteosarcoma (OS) and other solid tumours. Describing the current treatment landscape for primary and secondary bone cancer, Romness explains the potential of their own – OST-HER2, a bioengineered bacterial immunotherapy based on listeria. You can also listen to episode 184a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.